机构:[1]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Chaoyang District, China[2]Department of Oncology, Jilin Cancer Hospital, Changchun, China[3]Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[4]Department of Breast center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China河北医科大学第四医院[5]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang university School of Medicine, Hangzhou, Zhejiang Province, China[6]Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[7]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Longgang District, China深圳市康宁医院深圳医学信息中心中国医学科学院肿瘤医院深圳医院[8]Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China[9]Department of Medical Oncology, Meizhou People's Hospital, Meizhou, Guangdong Province, China[10]Phase I ward, Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin Province, China[11]Department of Phase I Clinical Trial Unit, The Fourth Hospital of Hebei Medical University, Shijiahuang, Hebei Province, China河北医科大学第四医院[12]Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Shanghai, China[13]Fosun Pharma USA, Inc, Lexington, MA[14]Shanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai, China
出处:
ISSN:
基金:
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
第一作者机构:[1]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Chaoyang District, China
推荐引用方式(GB/T 7714):
Li Qiao,Cheng Ying,Tong Zhongsheng,et al.FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA:
Li, Qiao,Cheng, Ying,Tong, Zhongsheng,Liu, Yunjiang,Wang, Xian...&Xu, Binghe.(2023).FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA:
Li, Qiao,et al."FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)